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number of intracranial lesions, presence of extra-cranial metastases and 
treatment approach, no variable signiﬁcantly inﬂuenced survival. How-
ever, aggressive salvage treatment with Gamma Knife radiosurgery did 
correlate with improved survival (Median survival 15.2 months after 
salvage radiosurgery, 8.2months following palliative whole brain radia-
tion therapy. P=0.03).
Conclusions: While the overall prognosis is poor for patients present-
ing with NSCLC and synchronous BM, our data suggests that a cohort 
of patients will be long-term survivors following aggressive treatment 
for intracranial disease. Aggressive salvage therapy for recurrent brain 
metastases also plays an important role in prolonging survival. Future 
studies are necessary to help identify patients most likely to beneﬁt 
from an aggressive approach. 
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Is re-irradiation effective in symptomatic local recurrence of non 
small cell lung cancer patients?
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Dokuz Eylul University Medical School Radiation Oncology Depart-
ment, Izmir, Turkey
Purpose: To evaluate retrospectively the effectiveness of re-irradiation 
in patients with non-metastatic non small cell lung cancer (NSCLC) at 
diagnosis who were previously irradiated with or without chemothera-
py and having local recurrence during follow-up.
Methods: In this study, 38 NSCLC patients having clinical ± radiologi-
cal progression retreated with hypofractionated radiotherapy between 
April 1992 and December 2006 were evaluated retrospectively. All 
patients were simulated before treatment. Radiotherapy ﬁeld covered 
the recurrent tumour with 1-2 cm safety margin. Two paralel or oblique 
opposite, isocentric ﬁelds were used while excluding spinal cord. 
The “adequate palliation” was deﬁned as more than 50% symptom 
palliation and “total/near total complete palliation” as 75-100%. The 
Log-rank method and Kaplan-Meier method was used for statistical 
analysis. 
Results: Median age was 58(33-80) years and all patients were 
male except 3. Median follow-up was 13.5 (4-65) months. The most 
frequent histology was squamous cell carcinoma (60.5%). Before 
reirradiation, chemotherapy was administrated to 9 patients without 
any response. Initially, median 30 Gy was given in median 10 frac-
tions. During reirradiation, a median total dose of 25 Gy (5 -30 Gy), in 
median 10 fractions (1-10) is delivered. The median interval between 
the initial radiation therapy and reirradiation was 35 (4-189) weeks. 
After hypofractionated reirradiation “adequate palliation” is obtained 
in 62.5% of the patients with cough, in 53% of patients with dispnea 
and in 50% of patients with hemoptysis and chest pain. “ Total / near 
total palliation” was noted in 35.6% of patients. After reirradiation, the 
median survival time was 11(1-237) weeks. The overall survival after 
initial diagnosis were 57.8% at 1 year and 28.8 % at 2 years and after 
reirradiation it was 8.7 % and 5.8 % respectively. In univariate analysis; 
age, tumour size, tumor location, interval between initial irradiation and 
reirradiation were evaluated for overall survival. A signiﬁcant survival 
advantage is seen in patients having an interval of more than 35 weeks 
(p=0.000). None of the patients had grade III-IV EORTC / RTOG side 
effects.
Conclusion: In non-metastatic NSCLC patients, reirradiation can 
provide adequate symptom relief. With 25 Gy hypofractionated reir-
radiation, total or near total palliation of symptoms can be obtained in 
almost one third of the patients having symptomatic local recurrence. 
Reirradiation of recurrent primary tumour can be used to improve the 
quality of life and prolong survival. Especially patients having long 
interval after initial radiotherapy can beneﬁt from this approach. How-
ever, studies including more patients are needed to prove the effective-
ness and economical advantages of this treatment modality.
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Purpose: To determine effectiveness of hypofractionated radiotherapy 
with or without cisplatin in the treatment of patients with non small cell 
lung cancer (NSCLC).
Methods: In this retrospective study, including the period July 1999-
September 2005, we evaluated 43 patients who were ineligible for 
multiagent chemotherapy with KPS ≥70 and tumour size preventing 
radical treatment. Radiotherapy, which involved primary tumour and 
metastatic lymph nodes, was given in 15 fractions over 3 weeks up 
to 45 Gy. Cord sparing was performed at 30 Gy (HIPO). Weekly 30 
mg/m2 cisplatin was concomitantly given with radiotherapy in appro-
priate patients (HIPOP). Kaplan Meier method was used for statistical 
analyses. 
Results: Median age was 58(36-80). The most frequent histology was 
squamous cell carcinoma (49%). There were 1(2%);8(19%);25(58%) 
and 9(21%) patients with stage IIB,IIIA,IIIB and stage IV respectively. 
The tumour size was ≥5 cm in 79% of patients. Neoadjuvant cisplatin-
based chemotherapy was given to 18 patients. There were 21 and 22 
patients in HIPO and HIPOP scheme, respectively. The median follow-
up was 9(1-24) months. Preradiotherapy symptoms were cough (49%), 
chest pain (49%), dyspne (37%) and hemoptysis (26%). According 
to treatment scheme, palliation rates were: 60%/100% in hemoptysis; 
71%/100% in dyspnea; 80%/91% in cough and 86%/86% in pain for 
HIPO/HIPOP. One-year overall survival (OS) was 67% and 45% for 
HIPOP and HIPO, respectively. No patients had severe RTOG grade 
III-IV side effects. 
Conclusion: HIPO/HIPOP schemes seem safe and effective modalities 
in locally advanced NSCLC patients who are not candidates for radical 
treatment. 
* This abstact is also presented in Balkan Union of Oncology 2006 
Meeting.
